Latest Prednisone Stories
BASEL and REINACH, Switzerland, September 2 /PRNewswire/ -- - CAPRA-2-Data Will be Used to File for US Marketing Approval Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM). The CAPRA-2 study (Circadian Administration...
MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida.
- New Progression-Free Survival Data To Be Presented at 2009 ASCO Annual Meeting Support Further Clinical Development of Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Poniard Management Team to Host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
McMaster University researchers have found patients with a very severe asthma benefit from injections of the antibody, mepolizumab.
- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium - SOUTH SAN FRANCISCO, Calif., Feb.
SAN FRANCISCO, Dec.
Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced positive incremental data from its ongoing Phase II clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer.
U.S. researchers say the use of modern immunosuppressive drugs eliminates the need for steroid therapy as early as seven days following a kidney transplant. Dr.
Cell Genesys, Inc. (Nasdaq:CEGE) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer.
DEAR DR. DONOHUE: I am a 78-year-old male who recently experienced a breaking out on my face and around my nose. Pimples came up. My physician diagnosed it as rosacea. He prescribed tetracycline and MetroGel ointment. The area cleared up. I wonder if I can stop taking the prescriptions.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.